Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739432 | 0.74 | MEN1 (0.43) | CNR2MAPK1CNR1HTTSMN1; SMN2 | |
| SCHEMBL2324385 | 0.70 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3249821 | 0.70 | CNR2 (0.41) | CNR2ADRA2AALDH1A1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5641612 | 0.69 | CNR2 (0.40) | CNR2ADRA2AALDH1A1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3254331 | 0.67 | CNR2 (0.39) | CNR2ADRA2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL28158922 | 0.66 | — | — | |
| SCHEMBL27964541 | 0.62 | — | — | |
| SCHEMBL13954289 | 0.61 | CNR2 (0.36) | CNR2MAPK1HCAR3 | |
| SCHEMBL1419363 | 0.61 | KDM4E (0.41) | CNR2MAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10994173 | 0.60 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670216-B2 | Cannabinoid-2 agonists | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC. | 2015-10-08 | — | — | US | disclosed |
| US-9062004-B2 | Cannabinoid-2 agonists | ALLERGAN, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011097553-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID - 2 AGONISTS | ALLERGAN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | CNR2 1/4885MAPK1 4008/4885ADRA2A 19/4885 |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | CNR2 1/4885MAPK1 3265/4885ADRA2A 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.